GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panacos Pharmaceuticals Inc (GREY:PANC) » Definitions » Debt-to-Equity

Panacos Pharmaceuticals (Panacos Pharmaceuticals) Debt-to-Equity : 3.45 (As of Sep. 2008)


View and export this data going back to 1998. Start your Free Trial

What is Panacos Pharmaceuticals Debt-to-Equity?

Panacos Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2008 was $7.05 Mil. Panacos Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2008 was $11.15 Mil. Panacos Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2008 was $5.27 Mil. Panacos Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2008 was 3.45.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Panacos Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

PANC's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Panacos Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Panacos Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacos Pharmaceuticals Debt-to-Equity Chart

Panacos Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 - 0.01 0.67

Panacos Pharmaceuticals Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.67 0.90 1.53 3.45

Competitive Comparison of Panacos Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Panacos Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacos Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacos Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Panacos Pharmaceuticals's Debt-to-Equity falls into.



Panacos Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Panacos Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2007 is calculated as

Panacos Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2008 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacos Pharmaceuticals  (GREY:PANC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Panacos Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Panacos Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacos Pharmaceuticals (Panacos Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
134 Coolidge Avenue, Watertown, MA, USA, 02472
Panacos Pharmaceuticals Inc is a biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat HIV and other human viral diseases.

Panacos Pharmaceuticals (Panacos Pharmaceuticals) Headlines

No Headlines